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Throughout the human life cycle, tissues are regenerated
either continuously to maintain tissue integrity in the face of
normal cell turnover or in response to acute or chronic damage
due to trauma or disease states. Blood, epithelia of skin and
tubular organs, hair and nails, and bone marrow are examples of
human tissues which regenerate continuously as well as in
response to damage. Bone, 1 muscle, 2 adrenal cortex 3 and kidney
epithelium 4 also regenerate in response to damage, and bone is
continually remodeled in response to stress vectors.
The response of many other vital tissues to damage,
however, is not regeneration but repair by the formation of
collagenous scar tissue. 5 Scar tissue interrupts the normal tissue
architecture, compromising· its function to varying degrees,
depending on the severity of the injury or disease process. Some
examples of diseases and injuries that cause serious impairment
by scarring are third degree bums, spinal cord injuries, diabetes,
macular degeneration of the neural retina and myocardial
infarction. These injuries and diseases are costly in terms of
healthcare dollars and potential decline in quality of life. Thus, a
major goal of biomedical science is to be able to restore the
structure and function of damaged or dysfunctional tissues that do
not regenerate naturally. Three major approaches to tissue
restoration have been developed: bionics, solid organ
transplantation, and, more recently, regenerative biology, which
includes cell transplantation, bioartificial tissue constructs and
regrowth of new tissues from injured residual tissues in vivo. The
purpose of this paper is to discuss these approaches with a
particular emphasis on regenerative biology.
BIONICS AND SOLID ORGAN TRANSPLANTATION

Over the past 50 years, we have made remarkable advances
in the use of bionic devices and solid organ transplants as
replacement parts for failing tissues and organs.

Bionics
Bionics is the design and construction of mechanical,
electrical, or optical devices to replace or supplement natural
tissues and organs. Advances in materials science, engineering
concepts and microelectronics in the latter half of the 20th
century have led to the development of a number of highly
successful bionic replacements and supplements, such as artificial
joints, cardiac valves and pacemakers. 6-8 These prostheses are
well-tolerated by the body, rarely experience structural failure
and restore a large measure of functional normality.
However, there are a number of problems associated with
bionic devices.9 Even the best metal alloys and plastics available
cannot match the properties of natural tissues. Body fluids

corrode these materials, releasing fine particulates which elicit an
inflammatory response, causing the implants to lose their
attachment to the surrounding tissue. The current I 0 to 20 year
life expectancy of bionic devices, while fine for older persons,
means multiple surgical replacement procedures for younger
individuals who receive them. Finally, we are as yet unable to
engineer devices to replace such vital organs as the heart, kidney
and lung that can match the size, form and function of the natural
organs.

Solid organ transplantation
Autotransplantation is an ancient practice described over a
thousand years ago by the Indian physician, Sushruta, in a
procedure for rebuilding damaged noses and earlobes. 10
Successful allogeneic (between genetically different individuals
of the same species) solid organ transplants began with kidneys in
1954. Today, as our understanding of the immune system has
grown, almost every solid organ can be successfully transplanted
either singly or in combinations. The advantage of a solid organ
transplant is its morphological, structural, and functional identity
to the original. The five-year survival rate is high, approaching
90% for kidney transplants. 11 Some patients have lived nearly 30
years with kidney transplants, apparently having developed
peripheral tolerance for the donor organ.
The major drawbacks to solid organ transplants are an acute
shortage of donors 12 and the need to use immunosuppressants to
prevent rejection of the transplant. Current immunosuppressants
such as cyclosporine A, azathioprine and steroids have a variety
of undesirable side effects, including musculoskeletal disorders,
vascular disease, hypertension, diabetes, and leaving the body
open to infection. 11 Solving the problem of immune rejection
could potentially solve the donor shortage problem as well, by
making it possible to use animals as donors . Such xenotransplants
normally do not survive because they are subject to complementmediated hyperrejection within minutes or hours following
transplantation. 13 Thus, contemporary research on solid organ
transplantation is directed at finding ways to evade the immune
system without immunosuppression.
REGENERATIVE BIOLOGY

Regene.rative biology is the science of creating new tissues,
either in vitro or in vivo, to replace or regrow damaged tissues.
Regenerative biology encompasses three major research
approaches: transplantion of cells which will form new tissue in
the transplant site, implantation of bioartificial tissues constructed
in vitro and stimulation of regeneration from residual tissues in
vivo. 14 •15 All of these approaches usually involve the partial
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recapitulation of embryonic development. Thus, regenerative
biology draws heavily on the principles and concepts of
developmental biology.

Cell transplantation
In humans, cell transplants have been used clinically to
successfully repair articular cartilage of the knee and as therapy
for Parkinson's disease. Cells have been transplanted experimentally in animals as potential treatments for Alzheimer's
disease and for the replacement of damaged cardiac muscle.
Brittberg et a1. 16 have described the autoplastic
transplantation of chondrocytes to fill in limited full-thickness
defects of knee joint articular cartilage. In their technique, a small
biopsy of cartilage is taken from the injured surface by
arthroscopy, cultured and chondrocyte clones expanded in vitro.
Dissociated chondrocytes from these clones are then implanted
under a flap of periosteum sutured over the lesion site. Within the
defect, new cartilage is formed that stains with metachromatic
dyes and with fluorescent antibodies to type II collagen. Although
the new cartilage is presumably derived from the transplanted
cells, its origin from chondrocytes at the edges of the defect or
from osteogenic cells of the periosteal flap has not been ruled out.
Parkinson's disease results from the death of dopaminergic
neurons in the substantia nigra that project to the putamen and
caudate (basal ganglia) that, in turn, project to the motor cortex
and control motor function. Neurons of the putamen and caudate
require dopamine from the substantia nigra to fire properly, so
death of substantia nigra neurons results in loss of motor control
and the muscle rigidity and tremor characteristic of the disease.
Suspensions of dopaminergic ventral mesencephalic cells from 89 week fetuses have been injected into the putamen of patients to
treat severe Parkinson's disease. 17 Dopamine production by the
transplanted cells was assessed by PET (positronic emission
tomography) scan following the injection of 6L-18F-fluorodopa.
Five months after transplantation, dopamine levels in the putamen
had increased and symptoms of the disease were dramatically
alleviated.
Cholinergic tissue from a variety of sources (fetal basal
forebrain, nodose ganglion, intracortical adrenal chromaffin cells
and differentiated neuroblastoma cells) survived when injected
into the terminal areas of the forebrain cholinergic projection
system of rat models of Alzheimer's disease. The transplanted
neurons exhibited axonal outgrowth, formed extensive synapses
with host neurons, and significantly reversed deficits in cognitive
behavior. 18- 20
To test the feasibility of using cell transplants to replace
damaged cardiac muscle, suspensions of fetal cardiomyocytes
from mice bearing a lac-Z reporter transgene driven by the
cardiac heavy myosin promoter were injected into the uninjured
ventricular myocardium of genetically identical hosts.21 The
transplanted cells proliferated and differentiated into mature
cardiac muscle, as indicated by the expression of the lac-Z _
reporter. Electron microscopic analysis showed that the
differentiated cells formed intercalated discs, suggesting their
probable electrical coupling with host cardiac myofibers. Similar
results have been obtained after transplanting fetal
cardiomyocytes into the ventricular myocardium of dogs.22
None of the transplanted cells described above elicited an
immune response because none were "seen" by the immune
system. The donor cartilage cells were autogeneic (from the same
individual), the donor cardiac cells were syngeneic (from a
genetically identical individual) and the brain is an
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immunoprivileged site. To fully exploit the potential of cell
transplants, we need to be able to evade the immune system and
to solve the problem of a reliable source of donor cells, just as
with solid organ transplantation. In addition, there are difficult to
resolve ethical issues associated with the use of fetal tissues as
sources of transplantable cells. Recently, mouse embryonic stem
(ES) cells have been used as a renewable source of
cardiomyocytes for injection into the ventricular myocardium of
mdx dystrophic mice. 23,24 The transplanted cells were stably
integrated into the host cardiac muscle as judged by antidystrophin immunostaining. The use of a human ES cell line as a
source of cardiomyocytes would avoid the ethical controversies
associated with transplantation of fetal cardiomyocytes, but such
a cell line is not yet available.

Bioartificial tissues
Another way of restoring tissues is to construct them in
vitro, a process often referred to as "tissue engineering." The
construction of a bioartificial tissue requires both a cell source
and a supporting matrix that will either maintain the functions of
differentiated cells seeded into the matrix or promote the
differentiation of embryonic precursor cells. The ideal supporting
matrix is biodegradable so that it is replaced over weeks and
months with the natural matrix made by the cells. Collagens are
the predominant proteins of support tissues in the body. Collagen
I is plentiful, and easy to extract and mold into a variety of forms.
It is thus the most widely used matrix biomaterial for both
bioartificial tissues and stimulation of regeneration in vivo either
by itself or in combination with various glycosaminoglycans such
as chondroitin 6-sulfate. Other widely used matrix materials are
alginate, polydioxanone, poly(epsilon-caprolactone), poly(glycolic acid), and poly(lactic acid). All, except alginate (in
crosslinked form), are biodegradable. Some matrix materials,
such as poly(lactic acid) fibers, can be molded into the shape of
the tissue or organ to be constructed. The cells of a bioartificial
tissue can be autogeneic or allogeneic in origin. The advantage of
allogeneic cells (assuming that the immune rejection problem can
be solved) is that they can be cultured and banked in advance for
use in cases where there is not enough time to expand a patient's
own cells to construct the tissue. Autogeneic cells have the
advantage of not eliciting an immune response.
The immune system can be evaded by a bioartificial tissue
implant if it is constructed as a closed system; i.e., if the cells are
isolated by a nonbiodegradable matrix with a pore size that
allows nutrient and gas exchange but excludes T-cells and
antibodies. For example, a closed bioartificial pancreas has been
clinically tested in a 38-year-old male patient who had been
diabetic for 30 years.25 This construct consisted of highguluronic acid alginate microcapsules containing islet cells
harvested by collagenase digestion from eight cadavers. The
patient received a total dose of 15,000 encapsulated islets/kg
body wt implanted into the intraperitoneal cavity in two doses of
10,000 and 5,000 islets six months apart. Three months after the
second implantation, diabetic symptoms were markedly abated
and the patient was able to discontinue insulin injections.
Proinsulin levels, however, were borderline, suggesting that the
dose of islet cells/kg body wt should be increased. How long the
structural integrity of the microcapsules can be maintained and
how long the islet cells can survive within the capsules are two
important questions that have not yet been answered.
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Regeneration in vivo from residual tissues
Mechanisms of natural regeneration
Regeneration from residual tissues in vivo would avoid all
the disadvantages of bionic implants, organ and cell transplants
and bioartificial tissue and organ implants, because the new tissue
would be autogeneic and regrow with the same histological and
morphological architecture as the original.
Regeneration in vertebrates is accomplished by three
mechanisms. The first is the activation, proliferation and
differentiation of progenitor or stem cells set aside during
embryonic development for growth and regeneration later in life.
Well-known examples of such reserve cells are the osteogenic
cells of the periosteum and endosteum which regenerate bone, the
satellite cells which regenerate skeletal -muscle, the pericytes of
capillaries which regenerate smooth muscle, and the epithelial
stem cells, hematopoetic stem cells and bone marrow
mesenchymal stem cells which maintain tissue integrity in the
face of continual cell turnover. Recently, stem cell populations
have also been found in the brain, liver, and pancreas. 26- 28 The
function of the stem cells in vivo is unknown, but if these tissues
tum over slowly, the stem cells might be involved in replacing
them, although there is no conclusive evidence for such turnover.
Liver stem cells are known to be activated when hepatocyte
destruction is so extensive (e.g, by carbon tetrachloride
poisoning) that the liver cannot regenerate by compensatory
hyperplasia of hepatocytes. The connective tissue compartments
of all tissues are postulated to contain mesenchymal stem cells,
since a subpopulation of connective tissue cells from a wide
variety of tissues is capable of multipotent differentiation into
fibroblasts , osteocytes, chondrocytes, fat cells and skeletal
muscle when treated with dexamethasone. 29 These cells, too,
might replace tissue that turns over slowly. However, their
relationship to progenitor cells such as osteogenic and satellite
cells is unclear and there is no evidence they act as progenitor or
stem cells for regeneration in vivo after injury. In addition, the
range of phenotypes they form in vitro is not appropriate for
regeneration of some tissues such as cardiac muscle.
The second mechanism of vertebrate regeneration is to
create progenitor cells from differentiated cells by a process of
tissue matrix degradation and dedifferentiation of the liberated
cells. Liver regeneration is accomplished by dissolution of the
scanty liver tissue matrix and the minimal dedifferentiation of
hepatocytes, which enables them to reenter the cell cycle while
maintaining all their differentiated functions.30 In mammals, the
liver is the only tissue known to regenerate by partial dedifferentiation. The urodeles (salamanders and newts), however, are
unique among vertebrates in that they use dedifferentiation to
provide progenitor cells for the regeneration of a number of
tissues that other vertebrates are unable to regenerate, including
the neural retina, lens, cardiac muscle and complex structures
such as the upper and lower jaws, limbs and tails. Following
injury or amputation, the extracellular matrix (ECM) of these
tissues is degraded at the site of damage, liberating the cells of the
tissue. The liberated cells lose their phenotypic characteristics
and revert to embryonic-like blastema cells. These cells reenter
the cell cycle and proliferate to form a growing blastema, which
subsequently redifferentiates into the missing structures.
Interestingly, although the bone and muscle of urodele limbs
contain osteogenic and satellite progenitor cells that are the
source of regenerated bone and muscle following a
nonamputational injury, there is no direct evidence that these cells
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participate in the regeneration of appendages following
amputation.
The third mechanism is used to regenerate the spinal cord in
urodeles, an ability which is unique among vertebrates. 31 In
urodele spinal cord regeneration, the ependymal cells lining the
lumen of the cord undergo an epithelial to mesenchymal
transformation. The mesenchymal cells proliferate to bridge the
lesion. In addition, they provide an environment favorable for the
regrowth of severed axons and the establishment of functional
synapses on either side of the lesion.
Stimulation of regeneration where it does not occur naturally
There are two reasons, not mutually exclusive, why most
human tissues fail to regenerate. First, these tissues may have
cells capable of engaging in regeneration but their environment
may not contain the signaling molecules that stimulate
regeneration or there may be inhibitory signals that divert the
cells into a repair pathway. This includes situations in which
regeneration may occur under one set of physical circumstances
but not another, such as a bone fracture vs. regeneration of bone
across a large gap. Alternatively, nonregenerating tissues may
have the appropriate molecular environment for regeneration but
may lack cells capable of responding to this environment. In
either case, the tissues cannot recapitulate their embryogenesis.
Thus, achieving regeneration of damaged tissues in vivo requires
recreation of the embryonic environment in terms of cells,
signaling molecules, or both.
A current strategy to stimulate regeneration in cases where it
does not occur naturally is to bridge lesions with natural or
artificial matrices that promote the migration, proliferation and
differentiation of local regeneration-competent cells, or promote
the regrowth of severed axons. There has been some success in
applying this strategy to the regeneration of bone, dermis and
spinal cord.
Although bone will regenerate to restore continuity after a
fracture, it is unable to regenerate across a gap, such as that
created by surgical removal of a bone tumor, probably because
the sources of osteogenic cells, the periosteum, endosteum and
bone marrow do not have the proper substratum to migrate and
fill the gap. Calcium phosphate-based hydroxyapatite matrices
promote bone regeneration.3 2-34 The freshly made matrices are
malleable pastes and can be pressed into a defect where they
harden into a scaffold capable of temporarily substituting for
bone. These scaffolds are osteoconducting as opposed to
osteoinducing; i.e., the matrix supports the migration of
osteoblasts from the host periosteum and endosteum rather than
inducing osteogenic cells to become osteoblasts. The migrating
cells differentiate and deposit natural bone matrix that gradually
replaces the hydroxyapatite scaffold.
Hydroxyapatites have a high affinity for bone
morphogenetic proteins (BMPs, members of the transforming
growth factor-beta [TGF~] family) and osteoinductive matrices
have been prepared by adsorbing BMP fractions onto porous
hydroxyapatites. This BMP-hydroxyapatite composite induces
rapid bone differentiation in skull defects of adult baboons.34
Only porous hydroxyapatite in block form, as opposed to
particulate hydroxyapatite, is effective, showing the importance
of matrix geometry in bone induction. Other growth factors
known to be involved in skeletogenesis (other members of the
TGF~ family, insulin-like growth factor [IGF]-I, platelet-derived
growth factor [PDGF] , or fibroblast growth factor [FGF]), or
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combinations of these factors may be equally important in
inducing large-scale bone regeneration and need to be tested.
Biodegradable artificial matrices can induce dermal
regeneration in excisional skin wounds, but regeneration is
imperfect. These matrices typically consist of collagen or gelatin
sponges to which other ECM components, such as chondroitin 6sulfate or elastin, are added.35 -38 The matrix is overlaid with
either a meshed split-thickness epidermal graft or a suspension of
dissociated keratinocytes. Fibroblasts from the surrounding
dermis migrate into the artificial matrix and replace it with a
matrix that resembles, but is not identical to, normal dermal
matrix. These results clearly show that, given the appropriate
environment, the adult dermis has the capacity for regeneration.
However, it is not known whether the responding cells are the
same dermal fibroblasts that normally form scar tissue or a
subpopulation of regeneration-competent reserve cells that are
normally suppressed in favor of repair. There is some evidence,
based on differences in thymidine incorporation and pattern of
cell association in vitro, that hypodermal fibroblasts form the
granulation tissue of repair whereas dermal fibroblasts might be
the cells capable of regeneration.39 The presence of an artificial
dermal matrix in a wound might suppress proliferation of
hypodermal fibroblasts and promote proliferation of dermal
fibroblasts, leading to regeneration. The nature of the factors that
suppress either dermal fibroblast proliferation after wounding or
hypodermal fibroblast proliferation in the presence of an artificial
dermal matrix is unknown but could be investigated in vitro with
an artificial matrix system.
Fetal skin regenerates perfectly. Several studies suggest that
differences between fetal and adult skin in the proportions of
ECM molecules and the relative concentrations of TGFI3
isoforms are important in determining whether a wound scars or
regenerates. 40-42 Changing the relative concentrations of TGFI3
isoforms of mouse fetal skin toward those of the adult, and vice
versa, increases and decreases scarring, respectively.43,44 Thus
fetal skin is an important model for the design of an artificial
dermal matrix to promote the perfect regeneration of adult skin.
Regeneration of cut peripheral nerve axons in mammals is
promoted by factors resident in the Schwann sheath. 45,46
Mammalian spinal cord axons, however, do not regenerate, even
though they have the intrinsic capacity to do so. Their failure to
regenerate is due to inhibitory factors such as toxic proteins in
degenerating myelin, oligodendrites, and axonal surfaces,
calcium influx and associated toxic reactions, glutamate
excitotoxicity, cholesterol depletion (arachidonic acid pathway)
and astroglial scar formation. 31 ·47 Toxic axonal damage can be
prevented by cell membrane-protective agents such as methylprednisolone and lazaroids, which increase the chances for
functional recovery in humans if administered within the first
eight hours after injury to the cord.48,49
Functional axonal regeneration across spinal cord lesions in
neonatal rats occurs after transplanting fetal cord to bridge the
lesion, as demonstrated by anterograde and retrograde labeling of
axons with fluorescent dyes and by recovery of righting reflexes
and walking ability. 50 Partial functional recovery was achieved in
adult rats by bridging cord lesions with grafts of intercostal
nerves stabilized by a fibrin matrix impregnated with FGF- J.51
Rats could support their weight on the previously paralyzed
hindlimbs and displayed movement in all leg joints, but did not
recover coordinated locomotion. Inclusion of FGF-1 in the matrix
was essential; no functional regeneration took place in rats
implanted with intercostal nerve and fibrin alone.
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Our ultimate goal is to stimulate the regeneration of spinal
cord and other tissues using artificial matrices designed to
neutralize inhibitory factors and to exactly reproduce the
molecular environment which guided the initial development of
that tissue.
CONTEMPORARY AND FUTURE RESEARCH DIRECTIONS

Cell sources
Providing reliable sources of cells for cell transplants and
bioartificial tissue construction is a crucial issue that requires
establishing culture banks of proliferating stem, progenitor, or
differentiated cells which can be drawn upon as required. These
cells can be in their natural condition or be genetically engineered
to produce desired molecules. Many types of differentiated cells,
such as hepatocytes and islet cells, are difficult to expand in vitro.
Stem and progenitor cells are difficult to identify and purify.
Furthermore, not all the factors essential for their proliferation
and differentiation are understood. Thus, research on the factors
that control the entry of stem, progenitor and differentiated cells
into and progression through the cell cycle and the factors that
control the differentiation of specific cell phenotypes will be of
prime importance for the design of media that allow cell
expansion and differentiation. For example, a defined medium
containing hepatocyte growth factor (HGF), epidermal growth
factor (EGF), and TGFI3-l has recently been found to support the
proliferation of mature rat and human hepatocytes.52 The stem
cells harbored by the adult rat brain were identified as stem cells
because they proliferate in vitro in response to EGF to form
neurospheres.26,53 Single cells of these neurospheres plated in
medium without EGF will differentiate into neurons, astrocytes,
or oligodendrocytes. 53 ·54 The ability to culture these stem cells
and differentiate them into the three major cell types of the central
nervous system makes them a potentially unlimited source for
neural cell transplantation.

Materials science
Advances in materials science are essential for advances in
bionics , construction of bioartificial tissues and for stimulation of
regeneration in vivo.
Metal alloys and plastics that do not corrode, that have the
strength and plasticity of natural tissues, and which have surfaces
that do not trigger thrombosis will result in great improvements in
the function and durability of bionic implants. The brightest
future may be in the development of sensory devices such as
artificial cochleas and retinas , electronic blood pressure
regulators and devices that both sense and regulate concentrations
of physiologically important molecules such as glucose.
New biomaterials will be required for the construction of
better bioartificial tissue matrices and matrices that stimulate
regeneration in vivo. Such matrices must meet several criteria to
be useful. They must be "smart"; i.e., contain or be able to release
appropriate biological signaling information to promote and
maintain cell adhesion, differentiation and tissue organization. In
essence, we want to develop polymers that mimic the functions of
the embryonic or adult ECM. Thus, research on polymer
chemistry must be coupled with research on the molecular
biology of ECM signaling systems that regulate cell morphology
and function. For example, adhesive oligo peptide or carbohydrate
recognition sequences might be linked to artificial polymers.
Selectivity of cell adhesion to substrates could be achieved by
linking specific recognition sequences to nonadhesive polymers.
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Such adhesive selectivity would be desirable, for example, in
artificial blood vessels, where the materials used should support
the adhesion and migration of endothelial cells but not the
adhesion of platelets, which could trigger thrombosis. 55 Growth
factors might also be bound to polymer matrices and released as
the polymers degrade.56 If the matrix materials form a closed
system, they must allow the ready exchange of oxygen, nutrients,
waste products and molecules that regulate the metabolic and
synthetic activities of the cells, while immunoprotecting cells.
Directional alignment is another "smart" matrix property
that would be useful in bioartificial tissue construction or
regeneration in vivo. Controlled alignment of the elements of the
biomaterial would allow it to orient cells, by contact guidance, in
particular directions essential for the functio n of the tissue. For
example, circumferential orientation of smooth muscle cells
(which would be important for construction or regeneration of
tubular tissues such as blood vessels) entrapped in a forming
collagen matrix has been achieved in vitro by using a strong
magnetic field to orient the collagen fibrils as they form.57
Copolymers of collagen I and chondroitin 6-sulfate in which the
pore channels were aligned longitudinally produced superior
regeneration of peripheral nerves within guide tubes compared to
other directions of alignment.45
One of the most important properties of matrix materials is
controlled biodegradability. The most widely used matrix
material, collagen I, is susceptible to rapid degradation in vivo
and, therefore, is thermally or chemically crosslinked to increase
its stability before use. Glutaraldehyde is the most commonly
used chemical crosslinking agent because it provides the highest
stability. However, biomaterials crosslinked with glutaraldehyde
also induce cytotoxicity. Recent experiments suggest that
collagen I crosslinked with carbodiimide or acyl azide is more
biocompatible than collagen I crosslinked by glutaraldehyde. 58
Only a few other biodegradable polymers, such as poly(glycolic
acid), poly(lactic acid), polydioxanone and their copolymers, are
available today to make artificial matrices. These polymers have
the disadvantages of being relatively stiff and lacking chemically
active side chains for easy attachment of biologically active
molecules, crosslinkers, or drugs. New matrix biomaterials, based
on tyrosine-derived polycarbonates and polyarylates, have been
devised in which the backbone, side chain composition and length
can be varied to change thermal behavior, mechanical properties,
hydrophobicity and cell-polymer interactions.59 These materials
are hydrophobic and degrade slowly, over months to years.
Currently, they appear to be most useful in situations where a
long-term degradation profile is desired, such as in bone
regeneration.
Experimental biomaterials are also being investigated that
will undergo phase transformation at body temperature.60 For
example, outside the body such a material might be a liquid that
occupies only a small volume, but when injected into the body it
would transform at the higher temperature into a semisolid or
solid. If the transformation involved expansion in volume, only
small apertures would be required to implant large constructs.

Evasion of the immune system
Wider use of cell transplants and bioartificial tissue
implants, particularly open constructs, will require the ability to
avoid immune rejection . Several innovative and promising
methods have been explored for evasion of the immune system
without compromising its function. Donor transgenic animals
have been created which express immune regulatory molecules
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that inhibit the activation or synthesis of key proteins involved in
rejection. One of these is human decay acceleration factor
(hDAF) · which inhibits the hyperacute rejection caused by the
endothelial cell damage and vascular ischemia triggered by
activation of complement.6 1 Immunosuppressed monkeys, which
would normally hyperreject donor pig hearts within a matter of
minutes, survived for a median of 40 days after recei vi ng pig
hearts transgenic for hDAF.62
Another strategy has been to mimic immunoprivileged sites
such as the anterior chamber of the eye. Transplants are not
rejected at these sites because cytotoxic T -cells entering them are
killed. T-cell apoptosis is mediated by a protein, FasL, produced
by cells at the immunoprivileged site which binds to the Fas
receptor expressed on T-cell surfaces. 63 Syngeneic myoblasts
transfected with the FasL gene were cotransplanted with
allogeneic pancreatic islet cells under the kidney capsule of mice
rendered diabetic with streptozotocin.64 These fused to form
myotubes expressing FasL which killed infiltrating T-cells, thus
preventing rejection of the islets. The production of animals
carrying transgenes that regulate or inhibit the immune system is
also a potential way to solve the problem of renewable sources of
donor cells, tissues and organs.
Finally, perhaps the most intriguing strategies to pursue are
the production of antibodies directed at T-cell receptors which
recognize foreign cell surface major histocompatibility antigens
(MHCs) and the genetic engineering of "stealth" cells that do not
express surface MHC antigens. In either case, T-cells would be
blind to foreign cells transplanted alone or as part of a
bioartificial construct.

Stem and progenitor cells; stimulatory and inhibitory
factors for regeneration in vivo
A number of questions about reserve cells needs to be
answered. How ubiquitous are such cells in mammalian tissues?
Do they exist in every tissue? What are their identifying
characteristics that will enable us to recognize them? What is
their normal function in tissues that do not regenerate in response
to injury? Do the tissues in which they are located turn over
slowly and do these cells function to replace the cells that turn
over?
If stem or progenitor cells exist in every body tissue, but are
inhibited from participating in regeneration in most tissues
because of the presence of inhibitory molecules or the absence of
the appropriate stimulating molecules, the question of stimulating
regeneration becomes one of determining how to identify and
neutralize inhibitors, or of identifying and applying stimulators of
regeneration to nonregenerating tissue. One way to identify these
stimulatory and inhibitory molecules might be to construct eDNA
libraries from regenerating tissue mRNA and subtract them with
mRNA from uninjured tissue or tissue that responds to injury by
repair. The subtracted libraries would then be transfected into
cells, such as Chinese hamster ovary (CHO) cells, that would
express and secrete the proteins encoded by the cDNAs. The
conditioned medium from the culture of aliquots of these cells in
multiple wells could then be tested on bioassy systems for their
regeneration-promoting ability. Positive samples would be
sequenced and their human counterparts identified for use as
regenerative agents.
Mechanical load (tension, compression) is an important
factor which triggers the synthesis and/or release of molecular
signals important to regeneration, differentiation and
hypertrophy, particularly in musculoskeletal tissues. In some
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vertebrates, like the chicken or rat, muscle can regenerate from a
remaining short muscle stump. In the rat, for example,
regeneration from the stump of the gastrocnemius muscle is
correlated with the regeneration of an Achilles tendon which
connects to the regenerating muscle. The tension exerted on the
muscle stump by the Achilles tendon is thought to be an
important factor in regeneration of muscle.65
Mechanical stress causes hypertrophy of cardiac and
skeletal muscle and increases collagen synthesis by cardiac
fibroblasts . In human skeletal muscle tissue the hypertrophy is
associated with increased release of FGF-2.66 In cultured fetal rat
cardiac fibroblasts the increase in collagen synthesis is correlated
with enhanced responses to TGFI3 and IGF-1. 67 The transition
from tendon to fibrocartilage in bovine deep flexor tendon is
associated with increased expression and accumulatJion of two
proteoglycans, aggrecan and biglycan . The levels ofTGFI3 and of
mRNAs for these proteoglycans are increased by compression of
fetal tendon, suggesting that fetal tendon cells respond to
compression by increasing TGFI3 synthesis which, in tum,
stimulates production of proteoglycans characteristic of
fibrocartilage.68

Dedifferentiation
What if tissues do not regenerate because they lack reserve
cells? In this case, we would like to decipher the urodele technical
manual to understand how to create progenitor cells out of
differentiated cells via histolysis and dedifferentiation. Histolysis
and dedifferentiation have been most extensively studied in the
regenerating limbs of salamanders and newts. After amputation
of a limb, the tissue matrix at the amputation site, which is
predominantly composed of collagens, elastins and sulfated
proteoglycans, is degraded and replaced with a more embryoniclike matrix that is much richer in fibronectin, hyaluronic acid, and
tenascin. The degradation is accomplished by lysosomal acid
hydrolases, particularly acid phosphatase, and members of the
matrix metalloproteinase (MMP) family of which ·II have been
identified in mammals and chickens. MMP-9 (gelatinase b;
hydrolyzes gelatin, proteoglycan, and collagen types IV, V, VII,
and X) is upregulated within a few hours of amputation in
regenerating axolotllimbs6 9 and as early as two days in the adult
newt limb 70 . In both axolotl and newt, its expression declines
MMP3110a and
after formation of a conical blastema.
MMP3/10b (stromelysins 112; degrade fibronectin, laminin,
proteoglycan, and collagen types II, IV, V, IX, and X) are also
strongly upregulated as early as two days in regenerating newt
limbs. MMP3/l0a is weakly transcribed up to 8 days
postamputation then disappears by 15 days, which is when
blastema cells are just beginning to accumulate; whereas
expression of MMP3/10b continues through the palette stage70 .
The different expression patterns of these three MMP genes
suggests that they may have different roles in degradation of limb
ECM. Acid phosphatase is most strongly expressed during the
periods of dedifferentiation and blastema formation.7 1 The cell
types producing these proteases, however, have not yet been
identified.
The cells liberated from degrading matrix lose their internal
specializations, become mesenchyme-like, and reenter the cell
cycle. Little is known about the mechanisms of this
dedifferentiation. The act of liberation from mature ECM itself,
which likely involves breaking of ECM ligand-cell surface
receptor contacts, may play a role in starting the process.
Tenascin and two other anti -adhesive proteins, SPARC
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(osteonectin) and thrombospondin, promote reorganization of the
actin cytoskeleton in bovine arterial endothelial cells by
modulating adhesive contacts.7 2 Whether these proteins might
function to reorganize the cytoskeleton of amputated urodele limb
cells (particularly myofibers) is not known.
The cells of healing mammalian wounds also employ
proteases to remodel ECM. Like the regeneration blastema, the
early wound matrix is dominated by hyaluronate and fibronectin
but, unlike the blastema, it is replaced not by normal matrix but
by a matrix enriched in crosslinked collagen I. With the exception
of the minimal dedifferentiation exhibited by hepatocytes in
regenerating liver, mammalian cells are not known to
dedifferentiate in vivo after injury, although some cell types, such
as chondrocytes, will dedifferentiate under certain in vitro
conditions. Mammalian tissues, thus, would appear to react
differently to injury than urodele limb tissues. The nature of these
differences is largely unknown but could involve the ionic and
molecular composition of the injury environment, intrinsic
differences in the responses of the cells to that environment, or
both.
Recently, Tanaka, et al.73 have demonstrated what appears
to be an intrinsic difference between cultured mammalian and
newt myotubes in their response to high concentrations of serum.
Nuclei of cultured mammalian myotubes do not synthesize DNA,
regardless of the concentration of serum to which they are
exposed. Nuclei of cultured newt myotubes do not synthesize
DNA in low (5%) concentrations of serum but do so at a 20%
serum concentration . DNA synthesis is correlated with
phosphorylation of the retinoblastoma (Rb) protein by cyclindependent kinase 4/6, which causes it to dissociate from E2F
transcription factors, allowing these factors to activate genes that
drive the nuclei into S phase of the cell cycle.7 4 Thus, newt
myotubes appear to have heightened sensitivity to serum factors
that lead to phosphorylation of Rb. The nature of this sensitivity
is not known, but is not due to retention of sensitivity to FGF-2,
EGF, or other standard growth factors such as PDGF and IGF,
since DNA synthesis was not elicited by these growth factors.
The response is dependent, however, on the degree of contact of
myotubes with other cells. High-density cultures of myoblasts
surrounding the myotubes prevents them from synthesizing DNA
whereas low density cultures do not. 73 This suggests that contact
inhibition normally inhibits newt myotubes from seeing or
responding to stimulatory factors in serum and that amputation
and matrix remodeling relieves this inhibition. Much research
remains to be done to understand the process of dedifferentiation
and reentry into cell cycle by urodele cells participating in
regeneration, how these events might be linked and the
differences between these cells and those of healing mammalian
wounds.
Finally, we need to understand how limb blastema cells are
maintained in a dedifferentiated state and kept in the cell cycle.
Serum factors that cause newt myotube nuclei to synthesize DNA
are not sufficient to drive them through the G2/M transition. 73
Other factors, not yet uneqivocally identified, provided by wound
epidermis and nerves are essential for complete cell cycling. 14
The embryonic-like ECM is thought to be instrumental in
maintaining blastema cells in an undifferentiated state, 75
probably by the nature of the contacts between cells and matrix.
The wound epidermis is also known to be essential for
maintaining cells in a dedifferentiated state,76 although whether
this is by its effect on cell cycling or is an independent effect is
unknown. The homeobox gene Msx-1 is expressed in blastema

journal of the Minnesota Academy of Science

Regenerative Biology
cells 77 and may be instrumental in repressing genes responsible
for differentiated function. Forced expression of Msx-1 in mouse
myoblasts downregulates MyoD, which maintains terminal
muscle differentiation and prevents them from differentiating.7 8

18.

CONCLUDING STATEMENT

Currently, we are very limited in what we can do to replace
tissues with cell transplants or bioartificial constructs, and in our
ability to stimulate the regeneration of tissues in vivo. But the
basic research approaches are now in place to make real
advances. Not too far into the 21st century, we may realistically
expect to be able to regenerate a number of vital tissues in a
clinical setting.
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